AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03111277 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: ExAblate Transcranial treatment
Description: Patients' head will be placed in a device to hold it still for the treatment. Patients will lie headfirst on the ExAblate table. The ExAblate Transcranial helmet will be placed on their head. A device will be placed over their head to hold it and the helmet still. The investigators will measure the study participant's heart, blood pressure, temperature, and breathing rate before the treatment begins. MRI scans will be taken to make sure the ultrasound waves will be aimed exactly within the target. The space between the rubber diaphragm and the helmet will be filled with water. The water will be chilled to avoid heating of the scalp and skull during the ultrasound treatment. A series of MR images will be taken to identify the target area, and plan the study treatment. The study investigators will decide on the area of participant's brain that will be treated. The ExAblate Transcranial system will compute a plan to cover the treatment area.
Study NCT04304508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2433334
Description: Tablet, taken orally once a day.
Study NCT04304508 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: BAY2433334 matching placebo
Description: Tablet, taken orally once a day.
Study NCT00703677 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lithium
Description: All participants will receive lithium. The dosage will be titrated over a 5-week period and then continued for an additional 6 months.
Study NCT01450514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pipamperone
Description: 15 mg PIP once daily per os on top of continued stable treatment with RIS or PAL
Study NCT01450514 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo sugar pill once daily per os on top of continued stable treatment with RIS or PAL
Study NCT02809352 — intervention group
Intervention type: BIOLOGICAL
Intervention: Human papillomavirus genotyping
Study NCT00208260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: FOLFIRI : Irinotecan : 180 mg/m² 90 min continuous perfusion during levorin d1 every 2 weeks
Study NCT00208260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX-4
Description: FOLFOX 4 : Oxaliplatine : 85 mg/m² 2h continuous perfusion during levorin d1 every 2weeks
Study NCT00208260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI-HD
Description: High Dose FOLFIRI : Irinotecan : 260 mg/m² in 90min continuous perfusion during levorin d1 every 2 weeks
Study NCT00208260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX-7
Description: FOLFOX 7 : Oxaliplatine : 130 mg/m² in 2h continuous perfusion during levorin d1 every 2 weeks
Study NCT00208260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: FOLFIRINOX : Oxaliplatine : 85 mg/m² 2h continuous perfusion followed by 1H rest followed by 90 min continuous perfusion of irinotecan : 180 mg/m² during levorin d1 every 2 weeks
Study NCT01523834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Induction Phase: Patients will receive panobinostat for 6 courses (1 course = 28 days). Consolidation phase (courses 7-12). Maintenance phase (course 13-end of therapy).~Panobinostat should be taken p.o. at the dose of 40 mg/day 3-times every week (QW) as part of a 4 week treatment cycle. The dose of panobinostat may be modified: the 1st dose adjustment consists in the modification of drug administration from 3 times every week (QW) to 3 times every other week (QOW). Levels lower than 30 mg 3 times QOW is not permitted.
Study NCT01535469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Fluconazole 800mg orally daily for 2 weeks, then 400mg daily for 8 weeks
Study NCT01963559 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine/prilocaine 1g (topical administration)
Description: Cutaneous blood flow measurement using laser Doppler
Study NCT04116437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib (BGB-3111) will be orally administered at a dose of 160 mg twice daily or 320mg once daily until disease progression, unacceptable toxicity, treatment consent withdrawal, or study termination.
Study NCT03555448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Once daily immunosuppression regimen
Description: Intervention focuses on the type of regimen, in this case the intervention arm will receive a once daily regimen for immunosuppression compared to the twice daily regimen.
Study NCT03555448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Twice daily immunosuppression regimen
Description: This is the arm which we are designating the standard, which will be the comparison to the active drug arm.
Study NCT02138617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours, Day 1 and Day 15 .
Study NCT02138617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 200-400 mg/m2 IV over 2 hours, Day 1 and Day 15
Study NCT02138617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: IV infusion over 90 minutes, dosed at 180, 260 or 310 mg/m2 based on genotype.
Study NCT02138617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (5 mg/kg IV infused as per institutional policy, IV, Day 1, 15)
Study NCT04613596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adagrasib
Description: Adagrasib 400 mg twice daily (BID) in combination with pembrolizumab (Cohort 1a)
Study NCT04613596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adagrasib
Description: Adagrasib 600 mg BID monotherapy (Cohort 1b)
Study NCT04613596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adagrasib
Description: adagrasib 400 mg BID in combination with pembrolizumab
Study NCT04613596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adagrasib
Description: Adagrasib 400 mg BID + pembrolizumab 200 mg every Q3W
Study NCT04613596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV Q3W
Study NCT02502435 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Observational study
Study NCT01166711 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coroflex Blue (BMS) followed by SeQuent Please (DEB)
Description: * standard techniques will be used~* maximal vasodilatation after nitro application~* baseline angiography with at least two orthogonal views (showing target lesion free of foreshortening or vessel overlap)~* 6 French guiding catheter at least~* target lesion will be crossed with standard guidewire~* direct stenting at the discretion of the investigator~* if pre-dilation, a commercially available balloon will be used (length not exceeding the stent to be implanted)~* full lesion coverage will be ensured (with one or more stents)~* only insert assigned stent type~* BMS needs to be fully embedded in vessel wall~* post-dilation with high pressure is required before treatment with DEB~* DEB will be inflated with nominal pressure (balloon equates to vessel diameter)~* length of DEB should exceed the BMS by 2-3 mm on each side~* if dissection, full length of dissection and optional additional stented area should be treated with additional DEB (to avoid geographic miss)
Study NCT01166711 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coroflex Please (DES)
Description: * standard techniques will be used~* maximal vasodilatation after nitro application~* baseline angiography with at least two orthogonal views (showing target lesion free of foreshortening or vessel overlap)~* 6 French guiding catheter at least~* target lesion will be crossed with standard guidewire~* direct stenting at the discretion of the investigator~* if pre-dilation, a commercially available balloon will be used (length not exceeding the stent to be implanted)~* full lesion coverage will be ensured (with one or more stents)~* only insert assigned stent type
Study NCT01913574 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture is applied three times a week for 20 minutes for 2 weeks (total 6 sessions). 9 Acupuncture points, CV12, CV13, P6, SP4, ST36(bilateral),LI4 (bilateral), LR3 (bilateral), ST34 (bilateral), and GB21(bilateral) are used, and CV12, CV13, ST36, and LR3 are electro-stimulated.
Study NCT01913574 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neurolytic celiac plexus block (NCPB)
Description: An anaesthetic test is performed injecting 2ml mepivacaine. After assessing the efficacy and safety of this test, 10 ml of absolute alcohol is injected via each needle.
Study NCT03838159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml.~The infusions must be mixed as soon as possible before the start of each infusion since the stability of paclitaxel beyond 24 hours is not known.~In-line filtration is obligatory since a small number of fibers within the acceptable limits of the USP Particulate Matter Test for LVP have been reported. Cellulose acetate filters of 0.22-micron pore size (such as IVEX II) can be used. The solution that shows excessive particulate matter must be rejected.
Study NCT03838159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml.~The infusions must be mixed as soon as possible before the start of each infusion since the stability of paclitaxel beyond 24 hours is not known.~In-line filtration is obligatory since a small number of fibers within the acceptable limits of the USP Particulate Matter Test for LVP have been reported. Cellulose acetate filters of 0.22-micron pore size (such as IVEX II) can be used. The solution that shows excessive particulate matter must be rejected.
Study NCT03838159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin must be administered at the end of the Paclitaxel infusion
Study NCT03838159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin must be administered at the end of the Paclitaxel infusion
Study NCT03838159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a soluble protein consisting of 4 polypeptide chains, which include 2 identical heavy chains and 2 identical light chains.~The administration of nivolumab infusion must be completed within 24 hours of preparation.
Study NCT03485469 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Hypnosis
Description: There ar 10 hypnosis sessions :~* 1st session of hypnosis : relaxation and orientation towards emotional cleansing.~* 2nd session of hypnosis: oriented towards digestion, physical and psychological~* 3rd session of hypnosis: oriented towards the feeling of security.~* 4th session of hypnosis: self-esteem oriented.~* 5th hypnosis session: oriented towards emotional management.~* 6th hypnosis session: oriented towards self-confidence.~* 7th hypnosis session: oriented towards the completion of the projects.~* 8th, 9th and 10th sessions: concern the learning of self-hypnosis and autonomy. A USB key containing the induction of a session of autohypnosis will be given to the subject to promote the continuation of home-made auto-hypnosis.
Study NCT03485469 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Care
Description: The dietary advice given during these dietary consultations is part of the standard care adapted to patients who have undergone bariatric surgery while increasing the frequency of consultations (Fractionation of meals, Volume of meals, Taking meals, Drinks, Food diversity)
Study NCT01913574 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neurolytic celiac plexus block (NCPB)
Description: An anaesthetic test is performed injecting 2ml mepivacaine. After assessing the efficacy and safety of this test, 10 ml of absolute alcohol is injected via each needle.
Study NCT03289013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard adhesive 1
Description: This strip consists of a standard hydrocolloid adhesive found in ostomy devices
Study NCT03289013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard adhesive 2
Description: This strip consists of a standard hydrocolloid adhesive found in ostomy devices
Study NCT03289013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LT-2
Description: Newly developed adhesive
Study NCT03289013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LT-21
Description: Newly developed adhesive
Study NCT04818255 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PET Biomarker Disclosure
Description: Participants receive information about whether they currently have elevated or not-elevated amyloid and/or tau based on recent PET imaging conducted as part of an affiliated research study (no additional imaging is required for this project). Participants meet with a licensed clinical neuropsychologist to discuss their biomarker status, the meaning of this information, and potential next steps to consider based of their status. Participants receive written summaries of this information, as well as resources as deemed necessary or as requested.
Study NCT03289013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LT-25
Description: Newly developed adhesive
Study NCT03289013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 33-20
Description: Newly developed adhesive
Study NCT01700257 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: CT scan & Early CDT Lung test
Study NCT01700257 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CT scan & Early CDT Lung test
Study NCT04094116 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ear wax syringing without pre ear oil treatment
Description: Active Comparator: ear wax syringing with pre ear oil treatment Sham Comparator: ear wax syringing without pre ear oil treatment
Study NCT04094116 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: ear wax syringing without pre ear oil treatment
Description: Active Comparator: ear wax syringing with pre ear oil treatment Sham Comparator: ear wax syringing without pre ear oil treatment
Study NCT01533961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCYX-7158
Study NCT01533961 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03252145 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PhysioTouch
Description: The PhysioTouch is a hand-held device that administers negative pressure under the treatment head, and gently pulls the underlying skin and subcutaneous tissue into the suction cup. This suction produces a stretch to the skin and in the subcutaneous tissue space. This action is thought to facilitate lymphatic flow from the interstitium into the lymphatic vessels, and mobilizes the superficial fascia.
Study NCT03252145 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Lymph Drainage (MLD)
Description: MLD is a practitioner-applied manual massage technique designed to decrease limb volume in patients with lymphedema by enhancing movement of lymph fluid, resulting in reductions in interstitial fluid.
Study NCT03750877 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: median approach
Description: spinal anesthesia with median approach; is the known classical method and it is aimed to reach the spinal area from the middle line.
Study NCT03750877 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: paramedian approach
Description: In spinal anesthesia with a paramedian approach, 1 cm lateral and 1 cm caudal to reach the spinal area.
Study NCT03091738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon Pill
Description: Patients with compensated cirrhosis and insomnia will be provided ramelteon
Study NCT03814902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic Tracking Device
Description: This commercially-available electronic tracking device uses Global Positioning System (GPS) technology to display the wearer's location on a mobile phone, tablet, or computer. The device may be securely attached to clothing and is designed to be worn by children with developmental disabilities. Parents may use the associated application to view the child's location when the device is turned on and active.
Study NCT04019873 — intervention group
Intervention type: DRUG
Intervention: Dolutegravir (DTG)
Description: DTG is a 2nd generation integrase strand transfer inhibitor. Subjects receiving DTG as a part of 2DR treatment will be included in the study.
Study NCT04019873 — intervention group
Intervention type: DRUG
Intervention: Lamivudine (3TC)
Description: 3TC is a nucleoside reverse transcriptase inhibitor. Subjects receiving 3TC as a part of 2DR treatment will be included in the study.
Study NCT04019873 — intervention group
Intervention type: DRUG
Intervention: Rilpivirine (RPV)
Description: RPV is a non-nucleoside reverse transcriptase inhibitor. Subjects receiving RPV as part of 2DR treatment will be included in the study.
Study NCT00950729 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Driving with running shoes
Description: Participant was asked to do all the experiments with their own running shoes
Study NCT00950729 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plaster cast
Description: The participant was ask to do all the experiments with a plaster cast molded on his right leg
Study NCT00950729 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Driving with Aircast
Description: The participant was ask to do all the experiments with a aircast on his right leg
Study NCT03763201 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: measurement of GITR
Description: serum and synovial fluid measurement of glucocorticoid-induced tumour necrosis factor receptor related protein
Study NCT02456025 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical tacrolimus
Description: Topical tacrolimus 0.01% twice daily for one month
Study NCT02456025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical tacrolimus
Description: Topical tacrolimus 0.01% twice daily for one month
Study NCT00256932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvimopan
Description: 0.5 mg
Study NCT01521039 — intervention group
Intervention type: PROCEDURE
Intervention: Blood samples
Description: 2-3 tablespoons of blood weekly for the first 100 days (about 14 weeks) following allogeneic transplant. In addition a blood sample will be obtained before starting the chemotherapy or radiation regimen for the transplant, in the day of the transplant and if your doctor suspects that you have acute graft-versus-host disease.
Study NCT04464564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786
Description: oral capsules
Study NCT00256932 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04240951 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sweat patch
Description: Flexible, epidermal, wearable skin patch to collect and analyze sweat
Study NCT04464564 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral capsules
Study NCT02748057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Study NCT02748057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Study NCT01267929 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The mirror neurons stimulation based VCD program
Description: The children receive the mirror neurons stimulation based VCD program and practice at home three times a day for six months.
Study NCT01267929 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The conventional physical therapy
Description: The children were randomly assigned to receive the conventional physical therapy for six months. Both experimental and control groups were measured their motor functions with GMFM-66 by an independent pediatric physical therapist who was blinded for treatment allocation at entry, the second month and the sixth month.
Study NCT03944863 — intervention group
Intervention type: DRUG
Intervention: Antibiotics
Study NCT01341899 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immunosuppression and stem cell transplantation
Description: Hematopoietic stem cells were mobilized with cyclophosphamide (CY, 2.0 g/m2) and granulocyte colonystimulating factor (10 μg/kg per day) and then collected from peripheral blood by leukapheresis and cryopreserved. The cells were infused after conditioning with CY (200 mg/kg) and rabbit antithymocyte globulin (4.5 mg/kg).
Study NCT01351207 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Eggs
Description: Comparison of a high saturated fat/low fiber meal alone, with eggs, and with a protein/cholesterol matched egg-free pudding
Study NCT01351207 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eggs
Description: Comparison of a high saturated fat/low fiber meal alone, with eggs, and with a protein/cholesterol matched egg-free pudding
Study NCT04808934 — intervention group
Intervention type: DRUG
Intervention: Apixaban
Description: Adults receiving apixaban
Study NCT04808934 — intervention group
Intervention type: DRUG
Intervention: dabigatran
Description: Adults receiving dabigatran
Study NCT04808934 — intervention group
Intervention type: DRUG
Intervention: rivaroxaban
Description: Adults receiving rivaroxaban
Study NCT04808934 — intervention group
Intervention type: DRUG
Intervention: VKAs
Description: Adults receiving VKA